FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to compositions used for delivery of bisphosphonate to a target and to development of simple and inexpensive compositions for delivery of bisphosphonates. Invention proposes variants of compositions containing at least one bisphosphonate and at least one compound as a delivery agent. Proposed compositions promote to delivery of bisphosphonates to chosen biological systems and improve bioavailability of bisphosphonates as compared with their administration without compound - a delivery agent. Also, invention proposes a method for preparing the claimed composition, standard medicinal formulation using the claimed composition and a method for administration of bisphosphonates in animal.
EFFECT: improved properties of compositions.
48 cl, 5 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED INDOLES, ANTIVIRAL ACTIVE COMPONENT, SYNTHESIS AND APPLICATION METHOD | 2010 |
|
RU2436786C1 |
| ARYL- AND HETEROARYL-SUBSTITUTED HETEROCYCLIC DERIVATIVES OF UREA, METHOD FOR INHIBITION OF RAF KINASE ACTIVITY AND PHARMACEUTICAL COMPOSITION | 1998 |
|
RU2265597C2 |
| METHOD FOR INHIBITION OF RAF KINASE-MEDIATED GROWTH OF TUMOR CELLS, HETEROCYCLIC UREA DERIVATIVES (VARIANTS), PHARMACEUTICAL COMPOSITION (VARIANTS) | 1998 |
|
RU2232015C2 |
| COMPOSITIONS AND MIXTURES FOR DELIVERY OF ACTIVE AGENTS | 2005 |
|
RU2403237C2 |
| 1,3,5-TRIAZINE DERIVATIVE AND A METHOD FOR USE THEREOF | 2016 |
|
RU2724333C2 |
| TAXANES, PHARMACEUTICAL COMPOSITIONS, INHIBITION METHOD | 2001 |
|
RU2265019C2 |
| METHOD OF INHIBITION OF OSTEOPOROSIS, PHARMACEUTICAL PREPARATION FOR OSTEOPOROSIS INHIBITION | 1995 |
|
RU2149631C1 |
| OPTIONALLY CONDENSED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE DERIVATIVES SUITABLE FOR TREATING INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES | 2015 |
|
RU2734261C2 |
| METHOD FOR INTRODUCING BISPHOSPHONATES | 2001 |
|
RU2288722C2 |
| OPTIONALLY CONDENSED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE DERIVATIVES SUITABLE FOR TREATING INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES | 2015 |
|
RU2719422C2 |
